Ideal Goals for Biosimilar Utilization

EP: 1.Biologics Utilization Impacting US Health Care Spending

EP: 2.Current Landscape of Biosimilar Use in US Healthcare Space

EP: 3.Interchangeability Impacting Biosimilar Uptake

EP: 4.The Impact of Payer Coverage and Reimbursement on Biosimilars

EP: 5.Navigating Biosimilar Uptake in New Patients

EP: 6.Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP: 7.Private Label Biosimilars

EP: 8.Biosimilars in the Commercial Sector

EP: 9.The Influence of Employer Preferences And Adoption of Biosimilars

EP: 10.Out of Pocket Costs Associated with Biosimilar Use

EP: 11.Unmet Needs and Future Initiatives

Now Viewing

EP: 12.Ideal Goals for Biosimilar Utilization

EP: 13.Foreseeable Biosimilar Trends

EP: 14.Legislative Support for Biosimilars

EP: 15.Key Takeaways for Biosimilar Utilization

Video content above is prompted by the following:

• What are the ideal goals for biosimilar utilization?
  • Similar to small molecule brands and generics: does the reference product go away and biosimilars have the great majority of utilization?
  • Or does reference product stay on the market with pricing concessions?